Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Human papillomavirus DNA and antibodies to human papillomaviruses 16 E2, L2, and E7 peptides as predictors of survival in patients with squamous cell cervical cancer

P Viladiu, FX Bosch, X Castellsague, N Munoz, JM Escriba, E Hamsikova, V Hofmannova, E Guerrero, A Izquierdo, C Navarro, P Moreo, I Izarzugaza, N Ascunce, M Gili, MT Munoz, L Tafur, KV Shah, V Vonka

. 1997 ; 15 (2) : 610-619.

Language English Country United States

Document type Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc13009303

Grant support
IZ1914 MZ0 CEP Register

PURPOSE: To assess whether human papillomavirus (HPV) DNA detection in cervical cancer specimens, or antibodies to selected HPV 16 peptides are predictors of tumor recurrence and long-term survival in patients with squamous cell invasive cervical cancer. SUBJECTS AND METHODS: Four hundred seventy-one cases included in two population-based case-control studies underwent follow-up evaluation. The survival and cause of death were ascertained for 410 cases (87%), with a median follow-up time of 4.6 years after diagnosis. HPV DNA was assessed using an L1 polymerase chain reaction (PCR)-based system and Southern hybridization (SH) on scraped cytologic specimens or biopsies. HPV 16 antibodies to E2, L2, and E7 peptides were detected with enzyme-linked immunosorbent assay (ELISA). RESULTS: Clinical stage was the only independent prognostic factor for recurrence or survival. Although seropositivity to HPV 16 E7/3 peptide predicted a twofold excess risk of mortality (adjusted hazards ratio [HRa] = 2.0; 95% confidence interval [CI], 1.2 to 3.3), the association was restricted to stage I (HRa = 6.6; 95% CI, 1.2 to 37.6) and II (HRa = 5.9; 95% CI, 2.1 to 16.5) patients. The presence of HPV DNA (HRa = 0.9; 95% CI, 0.5 to 1.5), different estimates of the HPV viral load and the HPV type identified were not predictors of tumor recurrence or survival. CONCLUSION: The presence of antibodies to HPV 16 E7 proteins is of prognostic value in early-stage cervical cancer. Our results provide strong evidence that detection and typing of HPV DNA in cervical cells or tissues is not a prognostic factor for recurrence or survival.

Obsahuje tabulky

Bibliography, etc.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc13009303
003      
CZ-PrNML
005      
20190104125619.0
007      
ta
008      
130311s1997 xxud f 000 0|eng||
009      
AR
035    __
$a (PubMed)9053484
040    __
$a ABA008 $d ABA008 $e AACR2 $b cze
041    0_
$a eng
044    __
$a xxu
100    1_
$a Viladiu, Paul $u Institut Catala d'Oncologia, Servei d'Epidemiologia i Registre del Cancer, Barcelona, Spain
245    10
$a Human papillomavirus DNA and antibodies to human papillomaviruses 16 E2, L2, and E7 peptides as predictors of survival in patients with squamous cell cervical cancer / $c P Viladiu, FX Bosch, X Castellsague, N Munoz, JM Escriba, E Hamsikova, V Hofmannova, E Guerrero, A Izquierdo, C Navarro, P Moreo, I Izarzugaza, N Ascunce, M Gili, MT Munoz, L Tafur, KV Shah, V Vonka
500    __
$a Obsahuje tabulky
504    __
$a Literatura
520    9_
$a PURPOSE: To assess whether human papillomavirus (HPV) DNA detection in cervical cancer specimens, or antibodies to selected HPV 16 peptides are predictors of tumor recurrence and long-term survival in patients with squamous cell invasive cervical cancer. SUBJECTS AND METHODS: Four hundred seventy-one cases included in two population-based case-control studies underwent follow-up evaluation. The survival and cause of death were ascertained for 410 cases (87%), with a median follow-up time of 4.6 years after diagnosis. HPV DNA was assessed using an L1 polymerase chain reaction (PCR)-based system and Southern hybridization (SH) on scraped cytologic specimens or biopsies. HPV 16 antibodies to E2, L2, and E7 peptides were detected with enzyme-linked immunosorbent assay (ELISA). RESULTS: Clinical stage was the only independent prognostic factor for recurrence or survival. Although seropositivity to HPV 16 E7/3 peptide predicted a twofold excess risk of mortality (adjusted hazards ratio [HRa] = 2.0; 95% confidence interval [CI], 1.2 to 3.3), the association was restricted to stage I (HRa = 6.6; 95% CI, 1.2 to 37.6) and II (HRa = 5.9; 95% CI, 2.1 to 16.5) patients. The presence of HPV DNA (HRa = 0.9; 95% CI, 0.5 to 1.5), different estimates of the HPV viral load and the HPV type identified were not predictors of tumor recurrence or survival. CONCLUSION: The presence of antibodies to HPV 16 E7 proteins is of prognostic value in early-stage cervical cancer. Our results provide strong evidence that detection and typing of HPV DNA in cervical cells or tissues is not a prognostic factor for recurrence or survival.
590    __
$a bohemika - dle Pubmed
650    02
$a dospělí $7 D000328
650    12
$a protilátky virové $x krev $7 D000914
650    12
$a spinocelulární karcinom $x chemie $x mortalita $x patologie $x virologie $7 D002294
650    12
$a DNA virů $x izolace a purifikace $7 D004279
650    02
$a ELISA $7 D004797
650    02
$a ženské pohlaví $7 D005260
650    02
$a lidé $7 D006801
650    02
$a lidé středního věku $7 D008875
650    02
$a invazivní růst nádoru $7 D009361
650    02
$a staging nádorů $7 D009367
650    02
$a odds ratio $7 D016017
650    12
$a Papillomaviridae $x genetika $x imunologie $7 D027383
650    02
$a polymerázová řetězová reakce $7 D016133
650    02
$a prediktivní hodnota testů $7 D011237
650    02
$a prognóza $7 D011379
650    02
$a riziko $7 D012306
650    02
$a analýza přežití $7 D016019
650    12
$a nádory děložního čípku $x chemie $x mortalita $x patologie $x virologie $7 D002583
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Bosch, Francesc-Xavier $u Institut Catala d'Oncologia, Servei d'Epidemiologia i Registre del Cancer, Barcelona, Spain
700    1_
$a Castellsague, Xavier $u Institut Catala d'Oncologia, Servei d'Epidemiologia i Registre del Cancer, Barcelona, Spain
700    1_
$a Munoz, Nubia $u International Agency for Research on Cancer, Lyon, France
700    1_
$a Escriba, Josep Maria $u Institut Catala d'Oncologia, Servei d'Epidemiologia i Registre del Cancer, Barcelona, Spain
700    1_
$a Hamšíková, Eva $7 xx0052821 $u Institute of Hematology & Blood Transfusion, Prague, Czech Republic
700    1_
$a Hofmannová, Vanda $7 xx0074129 $u Institute of Hematology & Blood Transfusion, Prague, Czech Republic
700    1_
$a Guerrero, Eloisa $u The Johns Hopkins University School of Hygiene and Public Health, Baltimore, MD, USA
700    1_
$a Izquierdo, Angel $u Hospital de Santa Caterina, Girona, Spain
700    1_
$a Navarro, Carmen $u Consejería de Sanidad y Política Social, Murcia, Spain
700    1_
$a Moreo, Pilar $u Servicio Provincial de Sanidad, Zaragoza, Spain
700    1_
$a Izarzugaza, Isabel $u Departamento de Sanidad y Consume, Vitoria-Gasteiz, Spain
700    1_
$a Ascunce, Nieves $u Programa de Cancer de Mama, Pamplona, Spain $7 gn_A_00009222
700    1_
$a Gili, Miguel $u Facultad de Medicina, Universidad de Sevilla, Sevilla, Spain
700    1_
$a Munoz, Maria Teresa $u Servicio Territorial de Sanidad y Bienestar Social, Salamanca, Spain
700    1_
$a Tafur, Luis $u Universidad del Valle, Gali, Colombia
700    1_
$a Shah, Keerti V. $u The Johns Hopkins University School of Hygiene and Public Health, Baltimore, MD, USA
700    1_
$a Vonka, Vladimír, $d 1930- $7 jk01150642 $u Institute of Hematology & Blood Transfusion, Prague, Czech Republic
773    0_
$t Journal of Clinical Oncology $x 0732-183X $g Roč. 15, č. 2 (1997), s. 610-619 $p J Clin Oncol $w MED00002596
773    0_
$p J Clin Oncol $g 15(2):610-9, 1997 Feb $x 0732-183X
910    __
$a ABA008 $b B 1556 $y 3 $z 0
990    __
$a 20130311091447 $b ABA008
991    __
$a 20190104125815 $b ABA008
999    __
$a ok $b bmc $g 972121 $s 807555
BAS    __
$a 3
BMC    __
$a 1997 $b 15 $c 2 $d 610-619 $i 0732-183X $m Journal of clinical oncology $x MED00002596 $n J. clin. Oncol.
GRA    __
$a IZ1914 $p MZ0
LZP    __
$a 2013-03/gvbo

Find record

Citation metrics

Archiving options